Lonza to make COVID-19 vaccine in Portsmouth
Click here to view this article at the source publication
Drugmakers racing to make COVID-19 vaccines and therapies are seeking out specialized manufacturers like Moderna’s partner Lonza Group that can scale up production to billions of doses needed to supply the world.
After the first batches of Moderna’s vaccine are produced in the U.S. in July, Lonza expects to produce initial “commercial volumes” at a site in Portsmouth, N.H., in December, followed by a location in Visp, Switzerland, in February, Chairman Albert Baehny said in an interview. Each line could make as many as 100 million doses per year.